Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic data of human nasopharyngeal carcinoma cells

ABSTRACT: LVTX-8, a peptide toxin synthesized from the cDNA library of the spider Lycosa vittata with 25 amino acids. In this study, we performed a series of cellular and molecular experiments such as cell toxicity, colony formation, and cell migration assays to exam the anticancer activity, selectivity and evaluate the cell toxicity of LVTX-8 in NPC cells (5-8F and CNE-2). The results suggested that LVTX-8 significantly inhibited cell proliferation and migration in both cell lines. To find the potential drug targets and further explain the molecular mechanisms underlying the anticancer capability of LVTX-8, high throughput proteomics profiling were performed.

ORGANISM(S): Homo Sapiens

SUBMITTER: Yong Zeng

PROVIDER: PXD050542 | iProX | Mon Mar 11 00:00:00 GMT 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Comparative Proteomics Identified EXOSC1 as a Target Protein of Anticancer Peptide LVTX-8 in Nasopharyngeal Carcinoma Cells.

Zhu Ganghua G Wang Lingxiang L Wang Xingyao X Dong Xiaoping X Yang Shu S Wang Jiaqi J Xu Siyuan S Zeng Yong Y

Journal of proteome research 20240503 6

Nasopharyngeal carcinoma (NPC) is a prevalent malignancy that usually occurs among the nose and throat. Due to mild initial symptoms, most patients are diagnosed in the late stage, and the recurrence rate of tumors is high, resulting in many deaths every year. Traditional radiotherapy and chemotherapy are prone to causing drug resistance and significant side effects. Therefore, searching for new bioactive drugs including anticancer peptides is necessary and urgent. LVTX-8 is a peptide toxin synt ...[more]

PMID: 38700954

Similar Datasets

Antipsychotic Drug Trifluoperazine as a Potential Therapeutic Agent against Nasopharyngeal Carcinoma

Project description:Trifluoperazine (TFP), a typical antipsychotic primarily used for treating schizophrenia, exhibits anticancer effect on several types of cancer in recent years. Nevertheless, the effect of TFP on na-sopharyngeal carcinoma (NPC) is still unknown. In this study, we aimed to evaluate if TFP can be the potential therapeutic agent against NPC and to identify its underlying molecular mechanisms. We used four NPC cell lines, namely TW01, TW03, TW04, and BM, to assess the anticancer effects of TFP using cytotoxicity, wound healing, colony formation, and cell invasion assays. RNA se-quencing combined with Ingenuity Pathways Analysis was performed to identify the mechanism by which TFP influences NPC cells. Our data revealed that TFP decreased NPC cell viability in a dose-dependent manner. The invasion and migration of NPC cells were inhibited by TFP. RNA sequencing showed several anticancer molecular mechanisms after TFP administration. It is promising that the antipsychotic drug TFP can be used as a potential therapeutic regimen in NPC treatment in the future.

2023-12-21 | GSE192860 | GEO

Gene expression data of nasopharyngeal carcinoma (NPC) cell and Thiostrepton treatment

Project description:Thiostrepton, a natural antibiotic, has recently been shown to be a potential anticancer drug for certain cancers, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were to investigate the anticancer effect of thiostrepton on NPC cells and to explore its underlying mechanism. Our results showed that thiostrepton reduced NPC cell viability in a dose-dependent manner. Thiostrepton inhibited the migration and invasion of NPC cells in wound healing and cell invasion assays. Thiostrepton effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. Thiostrepton may be a potential therapeutic agent for treating NPC in the future.

2019-03-06 | GSE127848 | GEO

Expression data from ectopic expression of BDH2 in Nasopharyngeal carcinoma (NPC) cell lines

Project description:Compare with normal nasopharyngeal epithelial cells, we found BDH2 was decreased in NPC cells, we found that BDH2 inhibited proliferation, colony formation, migration and invasion in NPC cells. We used microarrays to identify differential genes regulated by BDH2 in NPC cell lines.

2018-09-08 | GSE119642 | GEO

Expression data from ectopic expression of ACAT1 in Nasopharyngeal carcinoma (NPC) cell lines

Project description:Compare with normal nasopharyngeal epithelial cells, we found ACAT1 was decreased in NPC cells, we found that ACAT1 inhibited proliferation, colony formation, migration and invasion in NPC cells. We used microarrays to identify differential genes regulated by ACAT1 in NPC cell lines. We used microarrays to identify differential genes regulated by ACAT1 in NPC cell lines.

2020-07-28 | GSE155206 | GEO

RNA-seq data of nasopharyngeal carcinoma (NPC) cell and GO-PEG_erlotinib treatment

Project description:graphene oxide (GO) is found to be a promising novel anti-cancer drug carrier. Erlotinib, a tyrosine kinase inhibitor (TKI) acting on the epidermal growth factor receptor (EGFR), has been proved for locally advanced or metastatic non-small cell lung cancer (NSCLC) and in combination with gemcitabine for locally advanced or metastatic pancreatic cancer in 2004, but its study in nasopharyngeal carcinoma (NPC) is still limited. We designed functionalized GO, polyethylene glycol-coated GO (GO-PEG), as drug carriers, which was loaded with erlotinib and showed promising anticancer effect on NPC cells. Our results showed that GO-PEG-erlotinib effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. GO-PEG-erlotinib may be the potential therapeutic agents for treating NPC in the future.

2021-12-27 | GSE151195 | GEO

Clinacanthus nutans fractions exert anti-nasopharyngeal carcinoma effects: integrating untargeted metabolomics, network pharmacology, molecular docking and experimental validation

Project description:Background: Clinacanthus nutans (C. nutans), a Southeast Asian medicinal herb, has ethnopharmacological potential against nasopharyngeal carcinoma (NPC). This study aimed to elucidate the bioactive compounds, potential molecular targets, and regulatory pathways responsible for the anticancer activity of the Clinacanthus nutans leaves ethanol extract (E-CNL) fractions against NPC.Methods: HPLC-Q-TOF/MS/MS and GC-MS analyses, combined with chemometric modeling, were employed to comprehensively profile the phytochemical composition of E-CNL fractions. NPC-related targets were retrieved from GEO, GeneCards, and DisGeNET, and integrated into a PPI network constructed via Cytoscape. GO and KEGG enrichment analyses were performed to characterize key targets and pathways. Molecular docking (AutoDockTools, PyMOL) was used to assess compound–target binding. Pharmacological validation was conducted using NPC cell lines (HK-1, C666-1, and CNE2).Results: Sixty-one compounds and 794 potential targets were identified with 175 overlapping NPC-associated targets. PPI analysis highlighted ten hub genes, including TP53, STAT3, BCL2, CASP3, BCL2L1, MTOR, TNF, AKT1, ALB, and HIF1A. GO terms indicated roles in oxidative stress response, kinase regulation, phosphorylation, and MAPK cascade modulation, while KEGG analysis revealed significant associations with the PI3K–Akt, p53, TNF, FoxO, and VEGF signaling pathways. Molecular docking revealed strong affinities of the key compounds with PIK3CA, AKT1, TP53, and CDK1. In vitro assays confirmed that E-CNL fractions significantly inhibited NPC cell proliferation and migration, supporting their potential therapeutic relevance.Conclusion: E-CNL fractions exert their anti-NPC effects through multicomponent, multi-target, and multi-pathway mechanisms. These findings provide a scientific foundation for the further exploration of E-CNL fractions as promising treatment agents for NPC.

2026-01-05 | MTBLS13610 | MetaboLights

Microarray analysis of differentially expressed genes in bicalein-treated Nasopharyngeal carcinoma (HK-1) cell line

Project description:Baicalein is a bioactive compound that is found in an herbal plant, Oroxylum indicum, grown in Southeast Asia including Thailand. There are several reports investigating on the bioactivities of baicalein including an anticancer activity. However, there is no report on the anticancer activity of the baicalein in nasopharyngeal carcinoma. Thus, the aim of this study is to identify differentially expressed genes (DEGs) that are targets of baicalein in order to reveal cellular pathways and molecular mechanisms of the baicalein in nasopharyngeal carcinoma. In this study, NPC HK-1 cells were used as an NPC representative and treated with 10 and 20 µM baicalein for 24 hours before collecting cells for whole transcriptome profiles. The results revealed that a number of cellular pathways, based on KEGG enrichment analysis, are affected baicalein treatment such as focal adhesion and PI3K-Akt signaling pathway which were also phenotypically related to cell migration and invasion assays. Changes in transcriptome profiles of baicalein-treated HK-1 cells would provide insight on baicalein activity in NPC.

2022-01-26 | GSE127765 | GEO

Gene expression data of nasopharyngeal carcinoma (NPC) cell and Podoplanin (PDPN) siRNA treatment

Project description:Podoplanin, a transmembrane sialomucin-like glycoprotein, is now widely used as a marker for lymphatic endothelial cells and fibroblastic reticular cells in lymphoid organs, but its study in nasopharyngeal carcinoma (NPC) is still limited. The aims of this study were t characterize the role of PDPN in NPC. Our results showed that PDPN was expressed in most TW01 NPC cells. PDPN knockdown by siRNA decreased NPC cell proliferation, migration, and invasion. Knocking down PDPN results in suppression of NPC cell proliferation, migration, and invasion. PDPN may serve as a potential chemotherapeutic target for NPC treatment in the future.

2019-03-19 | GSE128502 | GEO

Human nasopharyngeal carcinoma

Project description:To uncover the oncogenic pathways of nasopharyngeal carcinoma, gene expression profiles of primary NPC cell strains and NPC-derived cell lines were conducted and analyzed in depth. Keywords: Oncogenesis Gene expression profiles of 9 primary NPC cell strains and 5 NPC-derived cell lines were analyzed. Forty Î¼g total RNA from one NPC sample was needed for a dye-swap experiment. Total RNA from 32 normal nasopharyngeal epithelial cell strains was pooled to serve as a universal reference.

2010-05-15 | E-GEOD-14262 | biostudies-arrayexpress

Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma

Project description:Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with extremely skewed ethnic and geographic distributions. Increasing evidence indicates that targeting the tumour microenvironment (TME) represents a promising therapeutic approach in NPC, highlighting an urgent need to deepen the understanding of the complex NPC TME. Here, we generated single-cell transcriptome profiles for 7,581 malignant cells and 40,285 immune cells from 15 primary NPC tumours and one normal sample. We revealed malignant signatures capturing intratumoural transcriptional heterogeneity and predicting aggressiveness of malignant cells. Diverse immune cell subtypes were identified, including novel subtypes such as CLEC9A+ dendritic cells (DCs). We further revealed transcriptional regulators underlying immune cell diversity, and cell-cell interaction analyses highlighted promising immunotherapeutic targets in NPC. Moreover, we established the immune subtype-specific signatures, and demonstrated that the signatures of macrophages, plasmacytoid dendritic cells (pDCs), CLEC9A+ DCs, natural killer (NK) cells, and plasma cells were significantly associated with improved survival outcomes in NPC. Taken together, our findings represent a unique resource providing in-depth insights into the cellular heterogeneity of NPC TME and highlight potential biomarkers for anticancer treatment and risk stratification, laying a new foundation for the precision therapies in NPC.

2020-07-20 | GSE150430 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data